Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : IRL201104
Therapeutic Area : Gastroenterology
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Revolo Highlights Preclinical Data On Sublingual ‘1104 in Allergic Disease
Details : ‘1104 (IRL201104) is a first-in-class immune-resetting peptide, which is being evaluated in phase 2 clinical trials for the treatment of eosinophilic esophagitis (EoE).
Brand Name : ‘1104
Molecule Type : Peptide
Upfront Cash : Not Applicable
October 21, 2024
Lead Product(s) : IRL201104
Therapeutic Area : Gastroenterology
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : IRL201104
Therapeutic Area : Dermatology
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Revolo Validates Atopic Dermatitis as Target for Preclinical Candidate ‘1104
Details : 1104 is a first-in-class peptide currently being evaluated in early-stage clinical trials for the treatment of atopic dermatitis.
Brand Name : ‘1104
Molecule Type : Peptide
Upfront Cash : Not Applicable
September 18, 2024
Lead Product(s) : IRL201104
Therapeutic Area : Dermatology
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : IRL201104
Therapeutic Area : Gastroenterology
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Revolo Data Validates Subcutaneous Administration of ‘1104 for Immune Disorders
Details : ‘1104 (IRL201104) is a first-in-class immune-resetting peptide, which is being evaluated in phase 2 clinical trials for the treatment of eosinophilic esophagitis (EoE).
Brand Name : ‘1104
Molecule Type : Peptide
Upfront Cash : Not Applicable
July 24, 2024
Lead Product(s) : IRL201104
Therapeutic Area : Gastroenterology
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : IRL201104
Therapeutic Area : Gastroenterology
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Revolo Receives Orphan Drug Designation for First-in-Class Peptide for EoE
Details : ‘1104 (IRL201104) is a first-in-class immune-resetting peptide, which is being evaluated in phase 2 clinical trials for the treatment of eosinophilic esophagitis (EoE).
Brand Name : ‘1104
Molecule Type : Peptide
Upfront Cash : Not Applicable
January 30, 2024
Lead Product(s) : IRL201104
Therapeutic Area : Gastroenterology
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : IRL201104
Therapeutic Area : Immunology
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Revolo Biotherapeutics Announces Data from Study of ‘1104 in Atopic Adults
Details : ‘1104 (IRL201104), a first-in-class peptide that is involved in resetting the immune system, has recently advanced through two Phase 2a trials; one in patients with eosinophilic esophagitis and one in patients with allergen sensitivity.
Brand Name : ‘1104
Molecule Type : Peptide
Upfront Cash : Not Applicable
October 25, 2023
Lead Product(s) : IRL201104
Therapeutic Area : Immunology
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : IRL201104
Therapeutic Area : Gastroenterology
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : ‘1104 (IRL201104), a first-in-class peptide that is involved in resetting the immune system, has recently advanced through two Phase 2a trials; one in patients with eosinophilic esophagitis and one in patients with allergen sensitivity.
Brand Name : ‘1104
Molecule Type : Peptide
Upfront Cash : Not Applicable
September 21, 2023
Lead Product(s) : IRL201104
Therapeutic Area : Gastroenterology
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : IRL201104
Therapeutic Area : Gastroenterology
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : ‘1104 (IRL201104), a first-in-class peptide that is involved in resetting the immune system, has recently advanced through two Phase 2a trials; one in patients with eosinophilic esophagitis and one in patients with allergen sensitivity.
Brand Name : ‘1104
Molecule Type : Peptide
Upfront Cash : Not Applicable
July 18, 2023
Lead Product(s) : IRL201104
Therapeutic Area : Gastroenterology
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : IRL201104
Therapeutic Area : Gastroenterology
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : 1104 (IRL201104) was derived from a natural immune-regulatory protein, Mycobacterium tuberculosis Chaperonin 60.1, involved in resetting the immune system. 1104 for the treatment of patients with eosinophilic esophagitis (EoE) and allergic disease.
Brand Name : ‘1104
Molecule Type : Peptide
Upfront Cash : Not Applicable
April 19, 2023
Lead Product(s) : IRL201104
Therapeutic Area : Gastroenterology
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : IRL201104
Therapeutic Area : Gastroenterology
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Revolo Biotherapeutics Announces Completion of Phase 2a Trial of ‘1104 in Allergic Disease
Details : 1104 (IRL201104) was derived from a natural immune-regulatory protein, Mycobacterium tuberculosis Chaperonin 60.1, involved in resetting the immune system. 1104 for the treatment of patients with eosinophilic esophagitis (EoE) and allergic disease.
Brand Name : ‘1104
Molecule Type : Peptide
Upfront Cash : Not Applicable
March 27, 2023
Lead Product(s) : IRL201104
Therapeutic Area : Gastroenterology
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : IRL201104
Therapeutic Area : Immunology
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : 1104 (IRL201104) is a first-in-class peptide derived from a natural immune-regulatory protein, mTB Chaperonin 60.1 that is involved in resetting the immune system. Currently developed for eosinophilic esophagitis and allergen sensitivity.
Brand Name : ‘1104
Molecule Type : Peptide
Upfront Cash : Not Applicable
February 06, 2023
Lead Product(s) : IRL201104
Therapeutic Area : Immunology
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?